Caris Life Sciences (CAI) Depreciation & Amortization (CF) (2024 - 2026)

Caris Life Sciences' Depreciation & Amortization (CF) history runs 3 years deep, the most recent figure standing at $5.1 million for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 27.64% year-over-year to $5.1 million in Q1 2026; TTM through Mar 2026 was $20.6 million, a 45.92% decrease from a year earlier, with the FY2025 full-year figure at $22.6 million, down 53.8% from the prior year.
• Depreciation & Amortization (CF) grew to $5.1 million in Q1 2026 per CAI's latest filing, from $4.3 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $11.6 million in Q2 2024 and bottomed at $4.3 million in Q4 2025.
• The 3-year median for Depreciation & Amortization (CF) is $6.7 million (2025), against an average of $7.4 million.
• Across the five-year window, Depreciation & Amortization (CF) plunged 53.33% in 2025 and declined 27.64% in 2026, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $9.1 million in 2024, then plunged by 52.83% to $4.3 million in 2025, then climbed by 18.45% to $5.1 million in 2026.
• Per Business Quant, the three latest CAI Depreciation & Amortization (CF) figures stand at $5.1 million (Q1 2026), $4.3 million (Q4 2025), and $4.9 million (Q3 2025).